Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CPX-POM |
Synonyms | |
Therapy Description |
CPX-POM (fosciclopirox) is a prodrug of ciclopirox with increased bioavailability, which may inhibit tumor cell proliferation and decrease tumor growth (Cancer Res 2018;78 (13 Suppl):Abstract nr 5882, PMID: 31113837). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CPX-POM | CPXPOM|CPX POM|Fosciclopirox | CPX-POM (fosciclopirox) is a prodrug of ciclopirox with increased bioavailability, which may inhibit tumor cell proliferation and decrease tumor growth (Cancer Res 2018;78 (13 Suppl):Abstract nr 5882, PMID: 31113837). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03348514 | Phase I | CPX-POM | Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04608045 | Phase I | CPX-POM | Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04525131 | Phase II | CPX-POM | Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors | Completed | USA | 0 |